Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United States amid President Donald Trump's tariff policies.

The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that could change if certain yet-unspecified policies are implemented that could “harm our industry’s ability to operate and innovate in America.

A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and more on those who work around the clock to take care of them. | A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and more on those who work around the clock to take care of them.

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight ...

The 700,000 square-foot facility is expected to create 400 high-wage manufacturing jobs once operational.

President Donald Trump's executive order on drug pricing may threaten Roche's planned $50 billion investment in the U.S. By lowering prices to align with other wealthy nations, while legal experts question the order's feasibility,

The committee awarded a grant to Genentech, a Roche subsidiary, to open a 420-worker, drug-manufacturing plant in the fast-growing part of southwestern Wake County. Roche pledged